Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis

Delgado, María Gabriela; Seijó, Susana; Yepes, Ismael; Achécar, L.; Catalina, María Vega; García–Criado, Ángeles; Abraldes, Juan G.; Peña, Joaquín de la; Bañares, Rafael; Albillos, Agustı́n; Bosch, Jaume; García‐Pagán, Juan Carlos

doi:10.1016/j.cgh.2012.01.012

Cited by 326 publications

(354 citation statements)

References 27 publications

Supporting

Mentioning

323

Contrasting

Unclassified

Order By: Relevance

“…52 In a study from Spain by Delgado et al involving 55 cirrhotic individuals with a mean MELD score of 12.8 and majority (75%) having partial PVT, complete PV recanalization was achieved in 45% of cases after a median duration of therapy of 6.3 months with vitamin K antagonists (VKA) or LMWH. 58 In this study also the only predictive factor for complete PV recanalization was early initiation of anticoagulation after diagnosis (<14 days). It has been shown that prolonging the duration of anticoagulation therapy can improve rates of complete PV recanalization.…”

Section: Anticoagulant Therapymentioning

confidence: 54%

“…Reviewing the limited studies reporting use of anticoagulation for PVT in patients with cirrhosis, complete recanalization has been described in 33%-45% while partial PV recanalization is observed in 15%-35% of cases 3,58,59 ( Table 2). In a study by Senzolo et al prospectively enrolling 56 individuals (35 treated and 21 controls) complete recanalization was achieved in 36% and partial recanalization in 27% individuals, after a mean of 5.5 months therapy with low molecular weight heparin (LMWH).…”

Section: Anticoagulant Therapymentioning

confidence: 99%

“…60 In most studies, recanalization is uncommon in patients with complete thrombosis, but anticoagulation still prevented the extension of the thrombus. 3,[58][59][60] An important objective in the management of PVT in cirrhotic patients awaiting liver transplantation is to achieve recanalization so that conventional end-to-end portal vein anastomosis is surgically possible. Another objective is to prevent extension of the thrombus to the splenic and superior mesenteric vein, since these veins can also be used to restore portal flow to the graft in case the main PV is thrombosed.…”

Section: Anticoagulant Therapymentioning

confidence: 99%

See 2 more Smart Citations

Portal Vein Thrombosis in Cirrhosis

Raja

Jacob

Asthana

2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Portal vein thrombosis (PVT) is being increasingly recognized in patients with advanced cirrhosis and in those undergoing liver transplantation. Reduced flow in the portal vein is probably responsible for clotting in the spleno-porto-mesenteric venous system. There is also increasing evidence that hypercoagulability occurs in advanced liver disease and contributes to the risk of PVT. Ultrasound based studies have reported a prevalence of PVT in 10-25% of cirrhotic patients without hepatocellular carcinoma. Partial thrombosis of the portal vein is more common and may not have pathophysiological consequences. However, there is high risk of progression of partial PVT to complete PVT that may cause exacerbation of portal hypertension and progression of liver insufficiency. It is thus, essential to accurately diagnose and stage PVT in patients waiting for transplantation and consider anticoagulation therapy. Therapy with low molecular weight heparin and vitamin K antagonists has been shown to achieve complete and partial recanalization in 33-45% and 15-35% of cases respectively. There are however, no guidelines to help determine the dose and therapeutic efficacy of anticoagulation in patients with cirrhosis. Anticoagulation therapy related bleeding is the most feared complication but it appears that the risk of variceal bleeding is more likely to be dependent on portal pressure rather than solely related to coagulation status. TIPS has also been reported to restore patency of the portal vein. Patients with complete PVT currently do not form an absolute contraindication for liver transplantation. Thrombectomy or thromboendovenectomy is possible in more than 75% of patients followed by anatomical end-to-end portal anastomosis. When patency of the portal vein and/or superior mesenteric vein is not achieved, only non-anatomical techniques (reno-portal anastomosis or cavo-portal hemitransposition) can be performed. These techniques, which do not fully reverse portal hypertension, are associated with higher morbidity and mortality risks in the short term. ( J CLIN EXP HEPATOL 2013;4:320-331)

show abstract

Section: Anticoagulant Therapymentioning

confidence: 54%

Section: Anticoagulant Therapymentioning

confidence: 99%

Section: Anticoagulant Therapymentioning

confidence: 99%

See 1 more Smart Citation

Portal Vein Thrombosis in Cirrhosis

Raja

Jacob

Asthana

2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…Regarding the efficacy and safety of anti-coagulant therapy in patients with cirrhosis and established PVT, available data consist of 5 case series with a total of 163 subjects [204,[207][208][209][210]: at month 6 of therapy, complete or partial recanalization occurred in 33-45% of patients, while extension of the thrombus was observed in <10%. Factors predicting recanalization were recent onset (<6 months) of the thrombus and partial PVT [211][212][213].…”

Section: Anti-coagulation For the Prevention/treatment Of Portal Veinmentioning

confidence: 99%

“…LMWH does not interfere with the MELD score and may be used until transplantation. A platelet count <50 × 10 9 /L and the use of VKA were the only factors more frequently observed in patients with bleeding related to anti-coagulation therapy [207]. Direct oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban and edoxaban) are now available as substitutes for VKA in non-liver disease patients, but their effectiveness/safety in patients with chronic liver disease remains to be assessed.…”

Section: Anti-coagulation For the Prevention/treatment Of Portal Veinmentioning

confidence: 99%

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Andriulli

Tripodi

Angeli

et al. 2016

Digestive and Liver Disease

View full text Add to dashboard Cite

a b s t r a c tPatients with cirrhosis present with hemostatic alterations secondary to reduced availability of procoagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent jury. The statements presented here highlight strengths and weaknesses of current laboratory tests to assess bleeding and thrombotic risk in cirrhotic patients, the pathophysiology of hemostatic perturbations in this condition, and outline the optimal management of bleeding and thrombosis in patients with liver cirrhosis.

show abstract

Hepatic Venous Outflow Syndromes and Splanchnic Venous Thrombosis

Elkrief

Valla

2019

Evidence‐based Gastroenterology and Hepatology 4e

View full text Add to dashboard Cite

Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis

Cited by 326 publications

References 27 publications

Portal Vein Thrombosis in Cirrhosis

Portal Vein Thrombosis in Cirrhosis

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Hepatic Venous Outflow Syndromes and Splanchnic Venous Thrombosis

Contact Info

Product

Resources

About